Crystal structure of bis-(β-alaninium) tetra-bromidoplumbate.

The title compound, poly[bis-(β-alaninium) [[di-bromido-plumbate]-di-μ-di-bromido]] {(CHNO)[PbBr]} or (-AlaH)PbBr, crystallizes in the monoclinic space group 2/. The (PbBr) anion is located on a general position and has a two-dimensional polymeric structure. The Pb center is holodirected.

Crystal structure of hexa-glycinium dodeca-iodo-triplumbate.

The crystal structure of hexa-glycinium tetra-μ-iodido-octa-iodido-triplumbate, (CHNO)[PbI] or (GlyH)[PbI], is reported. The compound crystallizes in the triclinic space group . The [PbI] anion is discrete and located around a special position: the central Pb ion located on the inversion center is holodirected, while the other two are hemidirected.

Artificial intelligence in therapeutic management of hyperlipidemic ocular pathology.

Hyperlipidemia has many ocular manifestations, the most prevalent being retinal vascular occlusion. Hyperlipidemic lesions and occlusions to the vessels supplying the retina result in permanent blindness, necessitating prompt detection and treatment. Retinal vascular occlusion is diagnosed using different imaging modalities, including optical coherence tomography angiography.

Alcohol-induced Golgiphagy is triggered by the downregulation of Golgi GTPase RAB3D.

The development of alcohol-associated liver disease (ALD) is associated with disorganized Golgi apparatus and accelerated phagophore formation. While Golgi membranes may contribute to phagophores, association between Golgi alterations and macroautophagy/autophagy remains unclear. GOLGA4/p230 (golgin A4), a dimeric Golgi matrix protein, participates in phagophore formation, but the underlying mechanism is elusive.

HIV-TB Coinfection: Current Therapeutic Approaches and Drug Interactions.

The co-occurrence of human immunodeficiency virus (HIV) and tuberculosis (TB) infection poses a significant global health challenge. Treatment of HIV and TB co-infection often necessitates combination therapy involving antiretroviral therapy (ART) for HIV and anti-TB medications, which introduces the potential for drug-drug interactions (DDIs). These interactions can significantly impact treatment outcomes, the efficacy of treatment, safety, and overall patient well-being.